Physician profile

Mark A Doloresco

Cardiovascular Disease · Colonial Heights, VA

NPI 1952326217

$4,267.83

in general payments reported to CMS, 2019-2025

37 companies · $904 in 2025

The $904 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,622.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $777.38 2019-2025
Amgen INC. $420.18 2019-2023 Repatha
Pfizer INC. $360.35 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $310.33 2019-2023
Abbott Laboratories $255.66 2020-2025 Mitraclip
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $202.16 2024-2025 Lifevest
Medtronic, INC. $156.22 2022
Astellas Pharma US INC $155.45 2019-2021
E.R. Squibb & Sons, L.L.C. $134.16 2019-2025 Camzyos
Merck Sharp & Dohme LLC $133.58 2021-2025 Verquvo
Irhythm Technologies, INC. $126.91 2023-2024 Zio Xt Patch, Zio Monitor
Boston Scientific Corporation $120.21 2019-2025 Watchman Flx, Watchman Access System
Novo Nordisk INC $118.38 2019-2025 Wegovy, Ozempic, Rybelsus
Medtronic USA, INC. $108.55 2020
Janssen Pharmaceuticals, INC $108.33 2019-2023 Xarelto
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $88.00 2020-2025 Wainua, Lokelma
Esperion Therapeutics, INC. $83.34 2020-2025 Nexletol
Kowa Pharmaceuticals America, INC. $79.15 2019-2022
Atricure, INC. $50.23 2021-2025 Epi-Sense Guided Coagulation System With Visitrax, Epi-Ease Epicardial Access System, Atriclip Laa Exclusion System
Regeneron Healthcare Solutions, INC. $42.92 2019-2023 Evkeeza
Heartflow, INC. $42.74 2025
Gilead Sciences, INC. $42.20 2019
Kestra Medical Technology Services, INC. $39.91 2022-2025 Assure Wcd
Medtronic Vascular, INC. $37.02 2019
Lundbeck LLC $30.44 2020-2021
Sanofi-Aventis U.S. LLC $29.26 2019-2021
Kiniksa Pharmaceuticals International, Plc $22.69 2024 Arcalyst
Inspire Medical Systems, INC. $22.67 2025 Inspire
Cardiva Medical, INC. $21.87 2021
Vifor Pharma, INC. $20.26 2019
Bayer Healthcare Pharmaceuticals INC. $20.20 2025
Livanova USA, INC. $19.92 2020
Akcea Therapeutics, INC. $19.68 2019
Lilly USA, LLC $18.81 2025 Mounjaro, Zepbound
Scpharmaceuticals INC. $17.76 2025
Lantheus Medical Imaging, INC. $16.45 2023 Definity
Abiomed $14.46 2024 Impella

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark A Doloresco

$4,267.83

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $904 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/270597/mark-a-doloresco

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.